TRIMTECH Therapeutics, a biotech developing small molecule therapeutics that selectively degrade protein aggregates for neurodegenerative diseases, has established a Scientific Advisory Board (SAB).

Alessio Ciulli and Adam Gilbert have been appointed as chair and member, respectively. The SAB will guide the development of TRIMTECH’s TRIMTAC and TRIMGLUE platforms, as well as its broader small molecule pipeline.

Nicola Thompson, CEO, said the board is “a pivotal step for us as a young company… Both will be instrumental in driving the development of our degrader platform and small molecule portfolio.”

Alessio Ciulli, chair of chemical and structural biology at the University of Dundee and founder of the Centre for Targeted Protein Degradation (CeTPD), brings experience in developing targeted protein degradation mechanisms and partnerships with industry.

He said: “TRIMTECH’s platform offers a new and incredibly promising approach, uniquely positioned to develop small molecule drugs for hard-to-treat targets that underpin many neurological diseases.”

Adam Gilbert, who has more than 30 years of pharmaceutical experience including leadership roles at Pfizer and co-inventor of ritlecitinib, will advise on the development of TRIMTECH’s degrader platforms. He added, “TRIMTECH’s approach to TPD… has the potential to address a real gap in the field by specifically targeting aggregated proteins.”

TRIMTECH aims to provide novel, cost-effective disease-modifying treatments for neurodegenerative disorders, where over 55 million people are affected globally.